Please note that any opinions, estimates or forecasts regarding Neuralstem, Inc.'s performance made by analysts are theirs alone and do not represent opinions, forecasts or predictions of Neuralstem, Inc. or its management. Neuralstem, Inc. does not by its reference below or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.
|
| ROCKVILLE, Md., Nov. 12, 2013 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) today reported financial results for the three months and nine months ended September 30, 2013 and provided a business and clinical update. (Logo: http://photos.prnewswire.com/prnh/20061221/DCTH007LOGO ) "The Company reached several major milestones in the third quarter. We completed patient dosing in our Phase Ib trial to treat major depressive disorder with NSI-189, our lead small molecule compound. We also ... |
Sign up for Breaking News Email Alerts
